trending Market Intelligence /marketintelligence/en/news-insights/trending/af0M9VBy33p2_RxVqZ-tEA2 content esgSubNav
In This List

CFDA approves clinical trials for Sihuan's erectile dysfunction drug

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


CFDA approves clinical trials for Sihuan's erectile dysfunction drug

The China Food and Drug Administration granted approval to Sihuan Pharmaceutical Holdings Group Ltd. for phase 1, 2 and 3 clinical trials of Fadanafil, a drug for benign prostatic hyperplasia-induced lower urinary tract symptoms and erectile dysfunction.

The drug is being developed by Shandong XuanZhu Pharma Co. Ltd., a unit of Sihuan Pharmaceutical.